Interestingly, bioinformatics analysis also demonstrated that death receptors, including DR4 and DR5, were overexpressed in CRC tumor tissues (Figure 1(A)), suggesting the potential of TRAIL as an anticancer agent for CRC. Here, TNFRSF10B is linked to colorectal carcinoma.